Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Head and Neck Squamous Cell Carcinoma (HNSCC)

Open-data reference.

11 US clinical trials · 6 currently recruiting

Active & Recent Trials

RECRUITING Phase 1 1,314 participants

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT05176483

RECRUITING Phase 2 410 participants

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences

NCT06295731

RECRUITING Phase 1 230 participants

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals

NCT05985655

RECRUITING Phase 2 120 participants

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

NCT06769698

RECRUITING Phase 2 80 participants

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Dan Zandberg

NCT04080804

RECRUITING Phase 1 27 participants

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America

NCT06943521

ACTIVE NOT RECRUITING Phase 1 350 participants

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

NCT04083599

ACTIVE NOT RECRUITING Phase 2 86 participants

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

RTOG Foundation

NCT03546582

ACTIVE NOT RECRUITING Phase 1 48 participants

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Boehringer Ingelheim

NCT05249426

ACTIVE NOT RECRUITING Phase 1 40 participants

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Arcus Biosciences

NCT05891171

COMPLETED Phase 1 204 participants

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

BeiGene

NCT04215978

Phase Distribution

PhaseTrial count
Early Phase 1 7
Phase 2 4

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Head and Neck Squamous Cell Carcinoma (HNSCC) Trial Landscape

ClinicalTrials.gov lists 11 US studies indexed under Head and Neck Squamous Cell Carcinoma (HNSCC), and 6 of those are currently open to recruitment — roughly 55% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Head and Neck Squamous Cell Carcinoma (HNSCC) shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 11 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Head and Neck Squamous Cell Carcinoma (HNSCC) is led by RTOG Foundation with 1 indexed trial, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Head and Neck Squamous Cell Carcinoma (HNSCC)?

PlainTrial tracks 11 US clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC), of which 6 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Head and Neck Squamous Cell Carcinoma (HNSCC)?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →